Asahi Life Asset Management CO. LTD. Invests $440,000 in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Asahi Life Asset Management CO. LTD. acquired a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the third quarter, Holdings Channel.com reports. The fund acquired 1,600 shares of the biopharmaceutical company’s stock, valued at approximately $440,000.

Several other hedge funds have also recently added to or reduced their stakes in the company. Ashton Thomas Private Wealth LLC bought a new position in Alnylam Pharmaceuticals during the second quarter valued at approximately $26,000. Allspring Global Investments Holdings LLC raised its position in Alnylam Pharmaceuticals by 572.0% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 143 shares during the period. Friedenthal Financial bought a new stake in Alnylam Pharmaceuticals in the third quarter worth $51,000. Altitude Crest Partners Inc. purchased a new stake in Alnylam Pharmaceuticals during the first quarter valued at about $30,000. Finally, Meeder Asset Management Inc. grew its stake in shares of Alnylam Pharmaceuticals by 1,237.5% during the second quarter. Meeder Asset Management Inc. now owns 321 shares of the biopharmaceutical company’s stock valued at $78,000 after buying an additional 297 shares during the last quarter. Institutional investors own 92.97% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently issued reports on ALNY. Citigroup raised their price target on Alnylam Pharmaceuticals from $291.00 to $342.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. The Goldman Sachs Group raised shares of Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and raised their price target for the stock from $198.00 to $370.00 in a report on Friday, August 16th. Canaccord Genuity Group upped their price objective on shares of Alnylam Pharmaceuticals from $357.00 to $366.00 and gave the company a “buy” rating in a research note on Friday, August 2nd. Wells Fargo & Company raised their target price on Alnylam Pharmaceuticals from $207.00 to $233.00 and gave the stock an “equal weight” rating in a research note on Friday, August 2nd. Finally, Bank of America lifted their price objective on Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the stock a “buy” rating in a research report on Monday, October 14th. Six investment analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $290.86.

Insider Activity at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 15,148 shares of the firm’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $270.00, for a total value of $4,089,960.00. Following the transaction, the chief executive officer now directly owns 73,441 shares in the company, valued at $19,829,070. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. In other news, CEO Yvonne Greenstreet sold 15,148 shares of Alnylam Pharmaceuticals stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $270.00, for a total transaction of $4,089,960.00. Following the transaction, the chief executive officer now owns 73,441 shares in the company, valued at $19,829,070. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Dennis A. Ausiello sold 20,250 shares of Alnylam Pharmaceuticals stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $262.00, for a total value of $5,305,500.00. Following the transaction, the director now owns 136 shares in the company, valued at $35,632. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 50,398 shares of company stock worth $13,595,460 over the last quarter. Company insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY stock traded up $3.91 during mid-day trading on Monday, hitting $288.77. The company’s stock had a trading volume of 71,490 shares, compared to its average volume of 866,008. The stock has a market cap of $36.53 billion, a price-to-earnings ratio of -106.29 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a 52-week low of $141.98 and a 52-week high of $304.39. The business has a 50-day moving average price of $274.43 and a 200 day moving average price of $222.40.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.61. The business had revenue of $659.83 million during the quarter, compared to analysts’ expectations of $447.22 million. Alnylam Pharmaceuticals’s quarterly revenue was up 107.0% compared to the same quarter last year. During the same period last year, the firm posted ($2.21) EPS. Equities research analysts predict that Alnylam Pharmaceuticals, Inc. will post -2.73 EPS for the current fiscal year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.